Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Carcinoma, Hepatocellular|Liver Diseases|Neoplasms by Histologic Type|Digestive System Neoplasms|Carcinoma|Liver Neoplasms|Neoplasms|Neoplasms by Site|Digestive System Diseases|Adenocarcinoma|Neoplasms, Glandular and Epithelial
DRUG: ABT-869|DRUG: Sorafenib
Overall Survival, From randomization until patient death; assessed monthly
Time To Progression (TTP), From randomization until patient progression; assessed every 6 weeks|Overall Response Rate (ORR), Assessed Every 6 weeks
The IDMC recommended discontinuation of the study, and, the protocol was amended to end study treatment.